{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:55:45Z","timestamp":1788742545120,"version":"build-2803163510"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.phrs.2026.108144","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:10:00Z","timestamp":1771359000000},"page":"108144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Mechanistic Rationale of Seladelpar\u2019s Clinical Efficacy through the Selective PPAR-\u03b4 Activation in Primary Biliary Cholangitis"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5086-0514","authenticated-orcid":false,"given":"Alessio","family":"Gerussi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0812-3959","authenticated-orcid":false,"given":"Matteo","family":"Fornai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108144_bib1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis","volume":"396","author":"Lleo","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.phrs.2026.108144_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1152\/physrev.00004.2023","article-title":"The liver as a central \"hub\" of the immune system: pathophysiological implications","volume":"105","author":"Ronca","year":"2025","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2026.108144_bib3","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI102222","article-title":"The relationship between serum lipids and skin xanthomata in 18 patients with primary biliary cirrhosis","volume":"28","author":"Ahrens","year":"1949","journal-title":"J. Clin. Invest"},{"issue":"5","key":"10.1016\/j.phrs.2026.108144_bib4","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.29717","article-title":"Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history","volume":"67","author":"Murillo Perez","year":"2018","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.phrs.2026.108144_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2021.104292","article-title":"The genetic architecture of primary biliary cholangitis","volume":"64","author":"Gerussi","year":"2021","journal-title":"Eur. J. Med Genet"},{"key":"10.1016\/j.phrs.2026.108144_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108144_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1440-1827.2009.02500.x","article-title":"Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement","volume":"60","author":"Nakanuma","year":"2010","journal-title":"Pathol. Int"},{"key":"10.1016\/j.phrs.2026.108144_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1089-3261(03)00135-1","article-title":"Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease","volume":"8","author":"Paumgartner","year":"2004","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.phrs.2026.108144_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2023.100188","article-title":"PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales","volume":"6","author":"Colapietro","year":"2023","journal-title":"J. Transl. Autoimmun."},{"key":"10.1016\/j.phrs.2026.108144_bib10","first-page":"682","article-title":"Management of Suboptimal Response in Primary Biliary Cholangitis Treatment","volume":"20","author":"Hirschfield","year":"2024","journal-title":"Gastroenterol. Hepatol. (N. Y)"},{"issue":"3","key":"10.1016\/j.phrs.2026.108144_bib11","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2026.108144_bib12","unstructured":"EMA. EMA recommends revoking conditional marketing authorisation for Ocaliva. \u3008http:\/\/ema.europa.eu\/en\/news\/ema-recommends-revoking-conditional-marketing-authorisation-ocaliva\u3009. Accessed September 28, 2025."},{"issue":"7","key":"10.1016\/j.phrs.2026.108144_bib13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2026.108144_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00795-013-0017-0","article-title":"PPAR\u03b3 ligand attenuates portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in primary biliary cirrhosis","volume":"46","author":"Nozaki","year":"2013","journal-title":"Med Mol. Morphol."},{"key":"10.1016\/j.phrs.2026.108144_bib15","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/bph.14886","article-title":"Rosiglitazone alleviates intrahepatic cholestasis induced by \u03b1-naphthylisothiocyanate in mice: The role of circulating 15-deoxy-\u039412,14-PGJ2 and Nogo","volume":"177","author":"Zhang","year":"2020","journal-title":"Br. J. Pharm."},{"issue":"6","key":"10.1016\/j.phrs.2026.108144_bib16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/1479164114548027","article-title":"The dual peroxisome proliferator-activated receptor alpha\/delta agonist GFT505 exerts anti-diabetic effects in db\/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects","volume":"11","author":"Hanf","year":"2014","journal-title":"Diab Vasc. Dis. Res"},{"issue":"9","key":"10.1016\/j.phrs.2026.108144_bib17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.phrs.2026.108144_bib18","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.3390\/ijms23094726","article-title":"Functional and Structural Insights into Human PPAR\u03b1\/\u03b4\/\u03b3 Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate","volume":"23","author":"Honda","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.phrs.2026.108144_bib19","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.phrs.2026.108144_bib20","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2026.108144_bib21","article-title":"Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis","volume":"15","author":"Martins","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2026.108144_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117303","article-title":"PPAR\u03b2\/\u03b4 attenuates hepatic fibrosis by reducing SMAD3 phosphorylation and p300 levels via AMPK in hepatic stellate cells","volume":"179","author":"Zhang","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2026.108144_bib23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep.23783","article-title":"Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis","volume":"52","author":"Lleo","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.phrs.2026.108144_bib24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41374-018-0045-4","article-title":"An impaired biliary bicarbonate umbrella may be involved in dysregulated autophagy in primary biliary cholangitis","volume":"98","author":"Sasaki","year":"2018","journal-title":"Lab Invest"},{"issue":"6","key":"10.1016\/j.phrs.2026.108144_bib25","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jhep.2018.08.020","article-title":"Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?","volume":"69","author":"Rodrigues","year":"2018","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108144_bib26","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/jcp.2004.023507","article-title":"Interferon gamma accelerates NF-kappaB activation of biliary epithelial cells induced by Toll-like receptor and ligand interaction","volume":"59","author":"Harada","year":"2006","journal-title":"J. Clin. Pathol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108144_bib27","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1136\/gut.34.9.1245","article-title":"Intercellular adhesion molecule-1 and MHC antigens on human intrahepatic bile duct cells: effect of pro-inflammatory cytokines","volume":"34","author":"Ayres","year":"1993","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.phrs.2026.108144_bib28","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI0214698","article-title":"Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis","volume":"109","author":"Kita","year":"2002","journal-title":"J. Clin. Invest"},{"issue":"11","key":"10.1016\/j.phrs.2026.108144_bib29","article-title":"Role of ductular reaction and ductular-canalicular junctions in identifying severe primary biliary cholangitis","volume":"4","author":"Overi","year":"2022","journal-title":"JHEP Rep."},{"key":"10.1016\/j.phrs.2026.108144_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jaut.2014.01.034","article-title":"Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells","volume":"50","author":"Huang","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2026.108144_bib31","article-title":"Single-Cell Characterization of Hepatic CD8+ T Cells in a Murine Model of Primary Biliary Cholangitis","volume":"13","author":"Han","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108144_bib32","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1038\/s41467-024-46654-5","article-title":"Targeting pathogenic CD8+ tissue-resident T cells with chimeric antigen receptor therapy in murine autoimmune cholangitis","volume":"15","author":"Zhu","year":"2024","journal-title":"Nat. Commun."},{"issue":"65","key":"10.1016\/j.phrs.2026.108144_bib33","doi-asserted-by":"crossref","first-page":"108406","DOI":"10.18632\/oncotarget.22658","article-title":"Regulatory T cells with a defect in inhibition on co-stimulation deteriorated primary biliary cholangitis","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2026.108144_bib34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","article-title":"Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators","volume":"347","author":"Issemann","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108144_bib35","doi-asserted-by":"crossref","unstructured":"1999, Nuclear Receptors Nomenclature Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell. 1999;97:161\u2013163. doi: 10.1016\/s0092-8674(00)80726-6.","DOI":"10.1016\/S0092-8674(00)80726-6"},{"key":"10.1016\/j.phrs.2026.108144_bib36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.phrs.2004.07.012","article-title":"An overview on biological mechanisms of PPARs","volume":"51","author":"Kota","year":"2005","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108144_bib37","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1128\/MCB.02266-05","article-title":"Peroxisome proliferator-activated receptor subtype- and cell-type-specific activation of genomic target genes upon adenoviral transgene delivery","volume":"26","author":"Nielsen","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2026.108144_bib38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu Rev. Med"},{"key":"10.1016\/j.phrs.2026.108144_bib39","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tibs.2004.04.006","article-title":"Schwabe JWR. Mechanism of the nuclear receptor molecular switch","volume":"29","author":"Nagy","year":"2004","journal-title":"Trends Biochem Sci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108144_bib40","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12017-020-08629-9","article-title":"Recent insights on the Role of PPAR-\u03b2\/\u03b4 in neuroinflammation and neurodegeneration, and its potential target for therapy","volume":"23","author":"Strosznajder","year":"2021","journal-title":"Neuromolecular Med"},{"issue":"4","key":"10.1016\/j.phrs.2026.108144_bib41","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/pr.58.4.5","article-title":"International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors","volume":"58","author":"Michalik","year":"2006","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.phrs.2026.108144_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2891-13-17","article-title":"Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications\u2013a review","volume":"13","author":"Grygiel-G\u00f3rniak","year":"2014","journal-title":"Nutr. J."},{"issue":"2","key":"10.1016\/j.phrs.2026.108144_bib43","doi-asserted-by":"crossref","first-page":"G120","DOI":"10.1152\/ajpgi.00158.2023","article-title":"Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis","volume":"326","author":"Choi","year":"2024","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108144_bib44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.beem.2007.09.004","article-title":"PPAR agonists: multimodal drugs for the treatment of type-2 diabetes","volume":"21","author":"Gross","year":"2007","journal-title":"Best. Pr. Res Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2026.108144_bib45","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature05894","article-title":"Macrophage-specific PPAR\u03b3 controls alternative activation and improves insulin resistance","volume":"447","author":"Odegaard","year":"2007","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2026.108144_bib46","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000646","article-title":"Peroxisome proliferator-activated receptor delta and liver diseases","volume":"9","author":"Yamazaki","year":"2025","journal-title":"Hepatol. Commun."},{"issue":"7","key":"10.1016\/j.phrs.2026.108144_bib47","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1194\/jlr.M046037","article-title":"PPAR\u03b4 activation attenuates hepatic steatosis in Ldlr-\/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity","volume":"55","author":"Bojic","year":"2014","journal-title":"J. Lipid Res"},{"issue":"5","key":"10.1016\/j.phrs.2026.108144_bib48","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1210\/en.2010-1468","article-title":"The PPAR\u03b2\/\u03b4 activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1\u03b1-Lipin 1-PPAR\u03b1 pathway leading to increased fatty acid oxidation","volume":"152","author":"Barroso","year":"2011","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.phrs.2026.108144_bib49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bcp.2015.01.016","article-title":"PPAR-\u03b2\/\u03b4 activation promotes phospholipid transfer protein expression","volume":"94","author":"Chehaibi","year":"2015","journal-title":"Biochem Pharm."},{"issue":"6","key":"10.1016\/j.phrs.2026.108144_bib50","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jceh.2019.06.004","article-title":"Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease","volume":"9","author":"Choudhary","year":"2019","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.phrs.2026.108144_bib51","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1042\/CS20110373","article-title":"Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet","volume":"123","author":"Fraulob","year":"2012","journal-title":"Clin. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108144_bib52","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/liv.15039","article-title":"Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis","volume":"42","author":"Kremer","year":"2022","journal-title":"Liver Int."},{"issue":"7","key":"10.1016\/j.phrs.2026.108144_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102056","article-title":"Selective PPAR\u03b4 agonist Seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway","volume":"298","author":"Kouno","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108144_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2020.06.006","article-title":"The selective PPAR-delta agonist Seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice","volume":"227","author":"Chu","year":"2021","journal-title":"Transl. Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108144_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16235","article-title":"Liver GPBAR1 associates with immune dysfunction in primary sclerosing cholangitis and its activation attenuates cholestasis in Abcb4-\/- Mice","volume":"45","author":"Di Giorgio","year":"2025","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.phrs.2026.108144_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093567","article-title":"GPBAR1\/TGR5 mediates bile acid-induced cytokine expression in murine Kupffer cells","volume":"9","author":"Lou","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.phrs.2026.108144_bib57","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1093\/nar\/gkv331","article-title":"The transcriptional PPAR\u03b2\/\u03b4 network in human macrophages defines a unique agonist-induced activation state","volume":"43","author":"Adhikary","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.phrs.2026.108144_bib58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/01.CIR.101.3.235","article-title":"Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators","volume":"101","author":"Pasceri","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2026.108144_bib59","doi-asserted-by":"crossref","first-page":"6712","DOI":"10.1073\/pnas.1031789100","article-title":"PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages","volume":"100","author":"Welch","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2026.108144_bib60","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cmet.2008.04.003","article-title":"Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance","volume":"7","author":"Odegaard","year":"2008","journal-title":"Cell Metab."},{"issue":"98","key":"10.1016\/j.phrs.2026.108144_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adn2717","article-title":"PPAR\u03b2\/\u03b4-orchestrated metabolic reprogramming supports the formation and maintenance of memory CD8+ T cells","volume":"9","author":"Bevilacqua","year":"2024","journal-title":"Sci. Immunol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108144_bib62","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1158\/2767-9764.CRC-24-0264","article-title":"Peroxisome proliferator-activated receptor \u03b4 suppresses the cytotoxicity of CD8+ T cells by inhibiting RelA DNA-binding activity","volume":"4","author":"Cen","year":"2024","journal-title":"Cancer Res Commun."},{"issue":"4","key":"10.1016\/j.phrs.2026.108144_bib63","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1365-2567.2010.03261.x","article-title":"Peroxisome proliferator-activated receptor delta agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis","volume":"130","author":"Kanakasabai","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.phrs.2026.108144_bib64","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.brainres.2010.12.059","article-title":"PPAR\u03b4 deficient mice develop elevated Th1\/Th17 responses and prolonged experimental autoimmune encephalomyelitis","volume":"1376","author":"Kanakasabai","year":"2011","journal-title":"Brain Res."},{"issue":"8","key":"10.1016\/j.phrs.2026.108144_bib65","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1084\/jem.20091663","article-title":"Peroxisome proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity","volume":"207","author":"Dunn","year":"2010","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.phrs.2026.108144_bib66","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jaut.2018.10.015","article-title":"The immunobiology of female predominance in primary biliary cholangitis","volume":"95","author":"Gerussi","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2026.108144_bib67","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.biochi.2016.11.010","article-title":"Roles of peroxisome proliferator-activated receptor \u03b2\/\u03b4 in skeletal muscle physiology","volume":"136","author":"Manickam","year":"2017","journal-title":"Biochimie"},{"issue":"5","key":"10.1016\/j.phrs.2026.108144_bib68","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3390\/ijms19051425","article-title":"An aPPARent functional consequence in skeletal muscle physiology via peroxisome proliferator-activated receptors","volume":"19","author":"Phua","year":"2018","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2026.108144_bib69","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cmet.2005.01.006","article-title":"A potential link between muscle peroxisome proliferator-activated receptor-alpha signaling and obesity-related diabetes","volume":"1","author":"Finck","year":"2005","journal-title":"Cell Metab."},{"issue":"10","key":"10.1016\/j.phrs.2026.108144_bib70","article-title":"Regulation of muscle fiber type and running endurance by PPARd","volume":"2","author":"Wang","year":"2004","journal-title":"elta. PLoS Biol."},{"key":"10.1016\/j.phrs.2026.108144_bib71","doi-asserted-by":"crossref","first-page":"9884","DOI":"10.1038\/srep09884","article-title":"A metabolomic study of the PPAR\u03b4 agonist GW501516 for enhancing running endurance in Kunming mice","volume":"5","author":"Chen","year":"2015","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.phrs.2026.108144_bib72","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cmet.2006.10.003","article-title":"PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes","volume":"4","author":"Schuler","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2026.108144_bib73","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.cardiores.2006.08.023","article-title":"The PPAR regulatory system in cardiac physiology and disease","volume":"73","author":"Finck","year":"2007","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.phrs.2026.108144_bib74","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nm1116","article-title":"Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy","volume":"10","author":"Cheng","year":"2004","journal-title":"Nat. Med"},{"key":"10.1016\/j.phrs.2026.108144_bib75","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.bbalip.2016.01.019","article-title":"PPAR\u03b2\/\u03b4 and lipid metabolism in the heart","volume":"1861","author":"Palomer","year":"2016","journal-title":"Biochim Biophys. Acta"},{"issue":"1","key":"10.1016\/j.phrs.2026.108144_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191365","article-title":"Differential actions of PPAR-\u03b1 and PPAR-\u03b2\/\u03b4 on beige adipocyte formation: A study in the subcutaneous white adipose tissue of obese male mice","volume":"13","author":"Rachid","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2026.108144_bib77","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12020-015-0590-1","article-title":"Short-term administration of GW501516 improves inflammatory state in white adipose tissue and liver damage in high-fructose-fed mice through modulation of the renin-angiotensin system","volume":"50","author":"Magliano","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.phrs.2026.108144_bib78","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s40265-024-02114-4","article-title":"Seladelpar: first approval","volume":"84","author":"Hoy","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2026.108144_bib79","unstructured":"EMA. EMA Approval Seladelpar. \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lyvdelzi\u3009. Accessed September 28, 2025."},{"key":"10.1016\/j.phrs.2026.108144_bib80","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000003603","article-title":"Long-term efficacy and safety of selective PPAR\u03b4 agonist seladelpar in primary biliary cholangitis: ASSURE interim study results","author":"Levy","year":"2025","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108144_bib81","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/HEP.0000000000000395","article-title":"Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study","volume":"78","author":"Hirschfield","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.phrs.2026.108144_bib82","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/apt.17755","article-title":"Open-label, clinical trial extension: Two-year safety and efficacy results of Seladelpar in patients with primary biliary cholangitis","volume":"59","author":"Mayo","year":"2024","journal-title":"Aliment Pharm. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2026.108144_bib83","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2022.02.033","article-title":"A phase II, randomized, open-label, 52-week study of Seladelpar in patients with primary biliary cholangitis","volume":"77","author":"Bowlus","year":"2022","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108144_bib84","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1074\/jbc.M110.138115","article-title":"Role of peroxisome proliferator-activated receptor \u03b4\/\u03b2 in hepatic metabolic regulation","volume":"286","author":"Liu","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.phrs.2026.108144_bib85","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4254\/wjh.v7.i8.1012","article-title":"Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease","volume":"7","author":"Souza-Mello","year":"2015","journal-title":"World J. Hepatol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108144_bib86","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00125-011-2401-4","article-title":"The peroxisome proliferator-activated receptor (PPAR) \u03b2\/\u03b4 agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells","volume":"55","author":"Serrano-Marco","year":"2012","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.phrs.2026.108144_bib87","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.phrs.2026.108144_bib88","article-title":"Efficacy and safety of Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis in the phase 2 placebo-controlled RESPONSE trial [AASLD abstract 700]","volume":"80","author":"Villamil","year":"2024","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.phrs.2026.108144_bib89","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2026.108144_bib90","doi-asserted-by":"crossref","unstructured":"Arustamyan G., Okawa M., Woo Y. et al, Distinct molecular mechanisms underlying ppar-\u03b4\u2013mediated alleviation of hepatocyte injury in primary biliary cholangitis. Pag. 3162 In: The Liver Meeting: 2025 Subject Categories Hepatology 82(S1):p S2465-S2554, October 2025. | DOI: 10.1097\/HEP.0000000000001494.","DOI":"10.1097\/HEP.0000000000001494"},{"issue":"1-2","key":"10.1016\/j.phrs.2026.108144_bib91","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejphar.2006.02.028","article-title":"Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet","volume":"536","author":"Nagasawa","year":"2006","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.phrs.2026.108144_bib92","doi-asserted-by":"crossref","first-page":"74364","DOI":"10.1155\/2007\/74364","article-title":"PPARs in the control of uncoupling proteins gene expression","volume":"2007","author":"Villarroya","year":"2007","journal-title":"PPAR Res."},{"issue":"S1","key":"10.1016\/j.phrs.2026.108144_bib93","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/HEP.0000000000001493","article-title":"Immunomodulation of cyto\/chemokines and T cell activation by PPAR agonists in PBC: a comparative analysis. Abstract n. 4405 In: the liver meeting: 2025 abstracts","volume":"82","author":"Roberts","year":"2025","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.phrs.2026.108144_bib94","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000635","article-title":"Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: Data from the GLIMMER study","volume":"9","author":"Smith","year":"2025","journal-title":"Hepatol. Commun."},{"issue":"2","key":"10.1016\/j.phrs.2026.108144_bib95","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-0039-1679918","article-title":"Mechanisms and treatments of pruritus in primary biliary cholangitis","volume":"39","author":"Shah","year":"2019","journal-title":"Semin Liver Dis."},{"issue":"1","key":"10.1016\/j.phrs.2026.108144_bib96","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.32599","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","volume":"77","author":"Xu","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2026.108144_bib97","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/08820139.2020.1785490","article-title":"Implication of Increased Serum IL-31 for Primary Biliary Cholangitis","volume":"50","author":"Mu","year":"2021","journal-title":"Immunol. Invest"},{"issue":"1","key":"10.1016\/j.phrs.2026.108144_bib98","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/HEP.0000000000000728","article-title":"Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis","volume":"80","author":"Kremer","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2026.108144_bib99","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14656566.2014.876992","article-title":"New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease","volume":"15","author":"Sahebkar","year":"2014","journal-title":"Expert Opin. Pharm."},{"issue":"5","key":"10.1016\/j.phrs.2026.108144_bib100","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1194\/jlr.M500002-JLR200","article-title":"Effects of peroxisome proliferator-activated receptor alpha\/delta agonists on HDL-cholesterol in vervet monkeys","volume":"46","author":"Wallace","year":"2005","journal-title":"J. Lipid Res"},{"issue":"10","key":"10.1016\/j.phrs.2026.108144_bib101","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3858\/emm.2012.44.10.066","article-title":"Peroxisome proliferator-activated receptor \u03b4 agonist attenuates hepatic steatosis by anti-inflammatory mechanism","volume":"44","author":"Lee","year":"2012","journal-title":"Exp. Mol. Med"},{"issue":"1","key":"10.1016\/j.phrs.2026.108144_bib102","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41598-017-00889-z","article-title":"Intestinal PPAR\u03b4 protects against diet-induced obesity, insulin resistance and dyslipidemia","volume":"7","author":"Doktorova","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108144_bib103","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1475-2840-12-82","article-title":"Selective peroxisome proliferator-activated receptor \u03b1 modulators (SPPARM\u03b1): the next generation of peroxisome proliferator-activated receptor \u03b1-agonists","volume":"12","author":"Fruchart","year":"2013","journal-title":"Cardiovasc Diabetol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108144_bib104","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/ncpendmet0397","article-title":"Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors","volume":"3","author":"Gervois","year":"2007","journal-title":"Nat. Clin. Pr. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.phrs.2026.108144_bib105","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.cmet.2017.04.029","article-title":"PPAR\u03b2 is essential for maintaining normal levels of PGC-1\u03b1 and mitochondria and for the increase in muscle mitochondria induced by exercise","volume":"25","author":"Koh","year":"2017","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.phrs.2026.108144_bib106","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1177\/0192623309336151","article-title":"Fenofibrate-induced muscular toxicity is associated with a metabolic shift limited to type-1 muscles in rats","volume":"37","author":"Okada","year":"2009","journal-title":"Toxicol. Pathol."},{"issue":"14","key":"10.1016\/j.phrs.2026.108144_bib107","article-title":"Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: A rare case report and literature review","volume":"97","author":"Wang","year":"2018","journal-title":"Med. (Baltim. )"},{"issue":"2","key":"10.1016\/j.phrs.2026.108144_bib108","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/toxsci\/kfn130","article-title":"PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742","volume":"105","author":"Faiola","year":"2008","journal-title":"Toxicol. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2026.108144_bib109","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bbalip.2010.11.002","article-title":"PPAR\u03b2\/\u03b4 activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells","volume":"1811","author":"Alvarez-Guardia","year":"2011","journal-title":"Biochim Biophys. Acta"},{"issue":"2","key":"10.1016\/j.phrs.2026.108144_bib110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/HYPERTENSIONAHA.110.164590","article-title":"Peroxisome proliferator-activated receptor \u03b2\/\u03b4 activation in adult hearts facilitates mitochondrial function and cardiac performance under pressure-overload condition","volume":"57","author":"Liu","year":"2011","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.phrs.2026.108144_bib111","first-page":"S301","article-title":"FRI-317 Pharmacokinetics, safety, and tolerability of Seladelpar in people with renal impairment","volume":"82","author":"Zhou","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2026.108144_bib112","unstructured":"FDA. Seladelpar prescribing information. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217899s000lbl.pdf\u3009. Accessed September 28, 2025."},{"key":"10.1016\/j.phrs.2026.108144_bib113","unstructured":"University of Liverpool. Hep Drug Interactions. \u3008https:\/\/www.hep-druginteractions.org\/\u3009. Accessed September 28, 2025."},{"key":"10.1016\/j.phrs.2026.108144_bib114","unstructured":"Pratt D., et al. Presented at: AASLD, The Liver Meeting; November 7\u201311, 2025. Oral 0213."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826000599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826000599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:24:46Z","timestamp":1777605886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826000599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":114,"alternative-id":["S1043661826000599"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108144","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic Rationale of Seladelpar\u2019s Clinical Efficacy through the Selective PPAR-\u03b4 Activation in Primary Biliary Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108144"}}